EUVIMEDEUVIMED entdecken
Crossref

Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making

Tugba Onalan, Fatih Colkesen, Fatma Arzu Akkus, Mehmet Emin Gerek, Filiz Sadi Aykan, Sevket Arslan

Allergy and Asthma Proceedings · 2025

DOI: 10.2500/aap.2025.46.250023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy and Asthma Proceedings, 2025. Verfasst von Tugba Onalan und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and. Hauptthemen laut MEDLINE: Asthma, Biological Products, Clinical Decision-Making, Anti-Asthmatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-life studies have shown the effects of biologic therapies on severe asthma. However, evidence for discontinuing treatment after targeted improvement remains limited.

Objective

This study investigated the factors associated with clinical remission in patients with severe asthma treated with biologics and explores physician decision-making with regard to the continuation or discontinuation of treatment after remission.

Method

A retrospective analysis was conducted on 65 patients with severe asthma who received biologics for at least 12 months between 2012 and 2024. Demographic and clinical data were reviewed, alongside physician-reported reasons for continued biologic use after remission and outcomes after treatment discontinuation.

Results

Clinical remission was achieved in 44.6% of the patients. Patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, allergic bronchopulmonary aspergillosis, or eosinophilic granulomatosis with polyangiitis, and those with waning effect did not discontinue biologics after remission due to physician judgment and concerns about exacerbating both asthma and coexisting conditions. The decision to continue biologic therapy after remission was influenced by nasal polyposis, intermittent use of high-dose inhaled corticosteroids, previous failed cessations, and certain other factors. Of the 13 patients who discontinued biologic treatment, 3 did so due to biologic nonresponse, all 3 with asthma‐chronic obstructive pulmonary disease overlap (ACO). Ten had achieved clinical remission before discontinuation. Treatment was restarted in one of these 10 patients due to exacerbations and loss of symptom control. Nonsevere exacerbations occurred in two of the remaining nine patients.

Conclusion

Biologics are highly effective in achieving remission in severe asthma. Achieving the desired goals does not require continuity of biologics in all patients. Attention to waning symptoms may contribute to the success of drug discontinuation. Individualized treatment plans, including consideration of comorbidities, adjustments in dose intervals, and nonbiologic treatment options, are essential for optimal outcomes with regard to cessation of biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsClinical Decision-MakingAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultRemission InductionSeverity of Illness IndexAgedTreatment OutcomePhysiciansWithholding TreatmentDecision Making

Substanzen

Biological ProductsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and.

Zitieren

APA

Onalan, T., Colkesen, F., Akkus, F. A., Gerek, M. E., Aykan, F. S., & Arslan, S. (2025). Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2025.46.250023

Vancouver

Onalan T, Colkesen F, Akkus FA, Gerek ME, Aykan FS, Arslan S. Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making. Allergy and Asthma Proceedings. 2025. doi:10.2500/aap.2025.46.250023

BibTeX
@article{Onalan2025,
  author = {Onalan, Tugba and Colkesen, Fatih and Akkus, Fatma Arzu and Gerek, Mehmet Emin and Aykan, Filiz Sadi and Arslan, Sevket},
  title = {Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making},
  journal = {Allergy and Asthma Proceedings},
  year = {2025},
  doi = {10.2500/aap.2025.46.250023}
}
Kostenlos starten →